Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athersys Inc.

www.athersys.com

Latest From Athersys Inc.

Japan's Healios Progresses Novel Cell Therapy For ARDS

Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.

Japan Regenerative Medicine

Japan Cell, Regenerative Therapy Environment ‘Exciting’ But Ongoing Dialog Needed

While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.

Japan Business Strategies

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

Regenerative Medicine Research and Development Strategies

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Part 3: Scrip spoke with companies working on cell and gene therapies and novel approaches to neurological diseases during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

Business Strategies Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Immune Disorders
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • BTHC VI Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Athersys Inc.
  • Senior Management
  • Gil Van Bokkelen, PhD, Chmn. & CEO
    John Harrington, PhD, EVP, CSO
    Laura Campbell, SVP, Fin.
    William Lehmann, JD, President and COO
    Manal Morsy, MD, PhD, SVP, Head of RA
    Robert Mays, PhD, VP Regenerative Medicine. Head Neuroscience
    Anthony Ting, PhD, VP Regenerative Medicine. Head Cardiopulmonary
    Raymond Starling, PhD, VP, Clinical Dev & Ops
  • Contact Info
  • Athersys Inc.
    Phone: (216) 431-9900
    3201 Carnegie Ave.
    Cleveland, OH 44115-2634
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register